In the brains of AD patients, expression of PKCδ is increased compared with the non-AD controls; PKCδ inhibition can also reduce Aβ production and rescue cognitive deficits in APPswe/PS1dE9 transgenic mice [10]. This evidence concerns the gene PRKCD and Alzheimer disease.